RBC Capital upgraded Sage Therapeutics (SAGE) to Sector Perform from Underperform with an unchanged price target of $4.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAGE:
- Sage Therapeutics reported another clinical setback, says H.C. Wainwright
- Sage Therapeutics reports results from Phase 2 DIMENSION Study
- Acumen appoints Schacterle as Chief Regulatory Officer, Head of Quality
- Sage Therapeutics price target lowered to $9 from $11 at Morgan Stanley
- SAGE Therapeutics Announces Strategic Reorganization Amid Executive Departures